Conjunctivitis Treatment Market Report 2025

The conjunctivitis treatment market size has grown steadily in recent years. It will grow from $4.73 billion in 2024 to $4.91 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to the globalization of eye care services, increased affordability and accessibility, demand for combination therapies, innovation in anti-inflammatory treatments, and growth in eye care infrastructure.

The conjunctivitis treatment market size is expected to see steady growth in the next few years. It will grow to $5.86 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to a focus on preventive healthcare, a rise in global incidence of conjunctivitis, growth in healthcare awareness and access, an increase in environmental allergens, expanding aging population. Major trends in the forecast period include regulatory shifts in treatment approvals, focus on comfort and symptom management, integration of artificial intelligence in diagnosis, demand for combination therapies, and growth in herbal and alternative remedies.

The conjunctivitis treatment market is poised for growth, fueled by the rising prevalence of conjunctivitis cases. Conjunctivitis, the inflammation of the conjunctiva, has witnessed an increase in instances, driving the demand for effective treatment options. Seeking medical attention and treatment for conjunctivitis has become more common, contributing to the growing conjunctivitis treatment market. As of June 2022, statistics from the American Medical Association indicated a higher prevalence of viral conjunctivitis compared to bacterial conjunctivitis among adults, accounting for 78% and 16%, respectively. In children, bacterial conjunctivitis was more prevalent at 71%, while viral conjunctivitis accounted for 16%. This upward trend in conjunctivitis cases emphasizes the need for treatment options, thereby bolstering the conjunctivitis treatment market.

The growing geriatric population is anticipated to drive the growth of the conjunctivitis treatment market. The geriatric population refers to elderly individuals within a given society or demographic. This age group is more susceptible to various eye conditions, including conjunctivitis. Factors such as weakened immune systems, pre-existing medical conditions, and age-related changes in eye health increase the risk of infections among the elderly. For example, in October 2022, a report from the World Health Organization (WHO), a Switzerland-based agency responsible for international public health, projected that one in six people is expected to be 60 or older by 2030 globally. By 2050, the number of people aged 60 and above is expected to reach 2.1 billion worldwide. Therefore, the rising geriatric population is driving the growth of the conjunctivitis treatment market.

Product innovation stands out as a pivotal trend gaining momentum in the conjunctivitis treatment market. Leading companies within this market are strategically focusing on the development of innovative products to reinforce their market presence. A noteworthy example is Johnson & Johnson Vision Care, a US-based division specializing in eye health and vision care. In March 2022, the company secured approval from the US FDA for ACUVUE Theravision with Ketotifen, a groundbreaking drug-eluting contact lens. This novel technology integrates ACUVUE daily disposable contact lenses with a well-established antihistamine, creating an entirely new category in the market. ACUVUE Theravision with Ketotifen is specifically designed to prevent ocular itch caused by allergic conjunctivitis while offering vision correction for eligible contact lens wearers without red eyes and with up to 1.0 D of astigmatism.

Major players in the conjunctivitis treatment market are also directing their efforts toward product development and launches, particularly in the realm of ophthalmic products. This category encompasses medical and pharmaceutical products tailored for the care and treatment of the eyes and vision-related conditions. A notable illustration comes from Harrow, Inc., a US-based company specializing in ophthalmic healthcare. In July 2023, Harrow, Inc. unveiled five innovative ophthalmic products in the United States, showcasing a diverse range of solutions for various eye conditions. Notable among these products are FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, targeting steroid-responsive inflammatory eye conditions, and NATACYN (natamycin ophthalmic suspension) 5%, the only FDA-approved topical ophthalmic antifungal medication addressing fungal blepharitis, conjunctivitis, and keratitis. TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% offers a solution for inflammatory ocular conditions requiring a corticosteroid with a risk of bacterial ocular infection. VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, designated as an orphan product, serves the treatment of vernal keratoconjunctivitis in both children and adults. Lastly, ZERVIATE (cetirizine ophthalmic solution) 0.24% addresses ocular itching associated with allergic conjunctivitis. This strategic product launch highlights Harrow, Inc.'s commitment to providing diverse and targeted solutions for a spectrum of ophthalmic conditions.

In March 2022, Théa Pharma Inc., a U.S.-based pharmaceutical company specializing in eye care products, successfully acquired seven branded ophthalmic products from Akorn Operating Company LLC. The specific financial details of this transaction were not publicly disclosed. This strategic acquisition represents a significant move by Théa Pharma Inc. to reinforce its presence as a key provider of specialized eye care products tailored to meet the needs of eye care professionals across the United States. Akorn Operating Company LLC, the seller, is a pharmaceutical firm based in the U.S. and focuses on manufacturing ophthalmic solutions, injectables, and oral liquid pharmaceuticals.

Major companies operating in the conjunctivitis treatment market include Pfizer Inc., Johnson and Johnson, AbbVie Inc., Novartis AG, Sanofi SA, Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Inc., Bausch Health Companies Inc, Santen Pharmaceuticals Co. Ltd, Lupin Limited, Allergan PLC, Alembic Pharmaceuticals Ltd, Akorn Inc., Micro Labs Ltd., Indoco Remedies Ltd., Mankind Pharma Ltd., AFT pharmaceuticals Limited, Ocular Therapeutics Inc., Sirion Therapeutics Inc., Jabs Biotech Pvt. Ltd., Atopix Therapeutics Ltd., JAWA Pharmaceuticals Pvt. Ltd., Eyevance Pharmaceuticals LLC, NicOx SA.

North America was the largest region in the conjunctivitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the conjunctivitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the conjunctivitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Conjunctivitis treatment encompasses medical interventions and therapies aimed at addressing the symptoms and root causes of conjunctivitis, commonly known as pink eye. These treatments involve the use of diverse medications to alleviate inflammation, manage symptoms, and prevent the spread of the infection.

The primary categories of drugs utilized for conjunctivitis treatment include antibiotics, antivirals, anti-allergic medications, and artificial tears. Antibiotics, specifically targeting bacterial infections, function by either eliminating bacteria or hindering their growth. They are frequently prescribed for conjunctivitis caused by bacterial agents to mitigate inflammation and eradicate the bacterial infection. These medications are applied orally or topically and are instrumental in addressing various conditions such as allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The usage of these medications spans across various end-users, including hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The conjunctivitis treatment research report is one of a series of new reports that provides conjunctivitis treatment market statistics, including the conjunctivitis treatment industry's global market size, regional shares, competitors with a conjunctivitis treatment market share, detailed conjunctivitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the conjunctivitis treatment industry. This conjunctivitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjunctivitis treatment market consists of revenues earned by entities by providing antibiotic therapy and eye-warming therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The conjunctivitis treatment market also includes sales of eye drops, ointments, ophthalmic steroids, non-steroidal anti-inflammatory drugs, and antihistamines, which are used in conjunctivitis treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.